[Pharmacological action of 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolinone hydrochloride (doxapram). 2. Peripheral action].
D000818:Animals; D001341:Autonomic Nervous System / Q000187:drug effects*; D003964:Diaphragm / Q000294:innervation; D004315:Doxapram / Q000494:pharmacology*; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects; D066298:In Vitro Techniques; D007422:Intestines / Q000187:drug effects; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009132:Muscles / Q000187:drug effects*; D009469:Neuromuscular Junction / Q000187:drug effects; D010862:Pilocarpine / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D012463:Saliva / Q000378:metabolism; D012584:Sciatic Nerve / Q000187:drug effects; D013085:Spermatic Cord / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D010862:Pilocarpine; D004315:Doxapram